Clinical Trials Logo

Gastric Cancer clinical trials

View clinical trials related to Gastric Cancer.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06392750 Completed - Gastric Cancer Clinical Trials

PWP1's Expression in Gastric Cancer.

Start date: May 1, 2021
Phase:
Study type: Observational

Background:Gastric cancer is a globally important disease and the fifth most diagnosed malignant cancer in the world. Because it is usually diagnosed at an advanced stage, gastric cancer has a high mortality rate, making it the third most common cause of cancer-related death. Hot spots of gastric cancer incidence and mortality exist in East Asia, Eastern Europe and South America. It is still an urgent problem to find new diagnostic and prognostic markers and better understand the molecular mechanism of gastric cancer. Although radical resection and systemic chemotherapy have shown great improvement, the prognosis of gastric cancer (GC) patients is still depressing due to malignant proliferation and metastasis. Therefore, it is urgent to clarify the potential molecular mechanism of gastric cancer progression, which will contribute to the development of targeted therapy. Effective induction of tumor cell apoptosis is the most important feature of a new chemical agent for cancer treatment. There is increasing evidence that the cell cycle can act in concert with apoptosis to cause cell death under certain cellular stress conditions. A comprehensive understanding of the relationship between apoptosis and cell cycle is essential for developing effective cancer therapies. PWP1 is also known as endonuclein, which contains five WD40 repeated domains and belongs to the WD40-repeated superfamily. It is highly expressed in human pancreatic adenocarcinoma, where it functions as a cell-cycle regulator. However, the normal function of Pwp1 is largely unknown. Previous research data show that PWP1 plays a key role in regulating biological functions such as RNA processing, signal transduction, gene expression, vesicle transport, cytoskeleton assembly and cell cycle progression. Whether the high expression of PWP1 is ubiquitous in tumors, the relationship between the high expression and clinicopathological factors of tumors, and the mechanism of PWP1 in tumors are still unclear. Further exploration of the molecular mechanism of PWP1 in GC may provide new ideas and therapeutic targets for GC treatment in the future, and benefit clinical patients.

NCT ID: NCT06365814 Completed - Gastric Cancer Clinical Trials

ERAS for Gastric Cancer Patients After NACT

Start date: October 1, 2023
Phase:
Study type: Observational

Background: Gastric cancer patients receiving neoadjuvant chemotherapy (NACT) are more vulnerable to perioperative stress. Enhanced recovery after surgery (ERAS) is widely used in surgical patients aiming at reducing stress responses. However, whether this approach is safe and feasible for gastric cancer patients received minimally invasive radical gastrectomy after NACT remained determined. So, the objective of this study is to investigate the effects of ERAS for this special group of gastric cancer patients. Materials and Methods: The data of gastric cancer patients who underwent minimally invasive radical gastrectomy after NACT were collected in this retrospective cohort study. Patients were divided into an ERAS group and a conventional group based on whether they received perioperative ERAS management. Propensity score matching was conducted to eliminate bias. Pre- and postoperative inflammatory and nutritional marker levels, postoperative complications, recovery indices and 3-year OS and RFS were observed.

NCT ID: NCT06337279 Completed - Gastric Cancer Clinical Trials

Systemic Oxidative Stress Score as a Predictor of Gastric Cancer Survival and Recurrence Risk

Start date: December 10, 2022
Phase:
Study type: Observational

The Systemic Oxidative Stress Score (SOSS) , a comprehensive score reflecting the oxidative stress conditions in the microenvironment, can independently and effectively predict tumor burden and long-term prognosis in GC patients. Nomograms based on SOSS provide a potential and promising model for risk stratification and guiding the implementation of treatment decisions.

NCT ID: NCT06337266 Completed - Gastric Cancer Clinical Trials

A Novel Online Calculator to Predict Long-term Survival and Recurrence Risk of Patients With Gastric Adenocarcinoma

Start date: January 1, 2023
Phase:
Study type: Observational

This study aimed to develop a novel Prognostic Oxidative Stress-Immune-Inflammatory Score (POSII Score) and introduce an innovative online calculator designed to predict long-term survival and assess the recurrence risk of gastric cancer (GC).

NCT ID: NCT06282484 Completed - Gastric Cancer Clinical Trials

A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous Lesions

Start date: September 1, 2022
Phase:
Study type: Observational

To explore the effects of gastric xanthoma on gastric cancer and its precancerous lesions, so as to better prevent the occurrence and development of gastric cancer.

NCT ID: NCT06281379 Completed - Gastric Cancer Clinical Trials

Complete Mesogastric Excision With D2 Lympadenectomy for Gastric Cancer:

Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Objective: To define complete mesogastric excision and compare our short term results for the first time in a different population. Study design:Randomised-controlled study Place and duration of the study: Gastroenterological Surgery Clinic,Health Sciences University,Basaksehir City Hospital,Istanbul,Turkey,from April to December 2023. Methodology: We compared short term results of open total gastrectomy+ mesogastrectomy with standard total gastrectomy + D2 lymph node dissection at a tertiary center in terms of peroperative results, histopathological findings and postoperative short- term outcomes with review of the literature. Conclusion: Our aim is to show that mesogastric excision is safe and has advantages over conventional D2 gastrectomy in means of not only peroperative and short-term outcomes, but also disease free survival.Our work is the first study from a different population of the world and our initial results can contribute to the literature for universalization.

NCT ID: NCT06250075 Completed - Gastric Cancer Clinical Trials

Effects of the Use of Probiotics on the Intestinal Microbiota of Patients With Gastric Cancer

PRONIC-G
Start date: December 12, 2020
Phase: N/A
Study type: Interventional

The objective of this randomized controlled, prospective clinical study, composed of 5 groups, G1, G2, G3, G4 and G5 is [Evaluate the intestinal microbiota profile, nutritional, immunological status and inflammatory profile, before and after total or partial removal surgery (gastrectomies) for gastric cancer, in a patient using probiotic supplements.] The main questions it aims to answer are: - probiotics are capable of modulating the immune response and microbiota in cancer patients who will undergo surgery - surgery itself alters the immunological pattern and microbiota of cancer patients Participants will be divided into groups for evaluation and the G1 intervention group will take probiotic capsules. The researchers will compare groups G1, G2 with G3 (negative control group) to see if there are differences between using probiotics or not, in controlling the immune response and if there are significant changes in their intestinal microbiota. Groups G4 and G5 will also be compared, where in these we will only measure the power of the use of probiotics in reducing surgical complications in the postoperative period.

NCT ID: NCT06208046 Completed - Gastric Cancer Clinical Trials

Predict 5-Year Survival in Elderly Gastric Cancer

Start date: July 1, 2023
Phase:
Study type: Observational

In this study, elderly patients with gastric cancer who underwent radical gastrectomy in Union Hospital Affiliated to Fujian Medical University from 2012 to 2018 were included as a derived cohort, and the training set and internal validation set were randomly divided by 4:1. Machine learning strategies of random forest, decision tree and support vector machine are used to construct survival prediction model. Each model was tested in an internal validation set and an external validation set consisting of patients from two other large medical centers.

NCT ID: NCT06205173 Completed - Colorectal Cancer Clinical Trials

Explored About Temperature Packing Care to Improve the Quality of Life for Chemotherapy Induced Peripheral Neuropathy (CIPN) in Colorectal Cancer and Gastric Cancer Patient

Start date: August 19, 2020
Phase: N/A
Study type: Interventional

Investigate the effectiveness of cold and hot compress interventions in reducing peripheral neuropathy induced by Oxaliplatin chemotherapy in colorectal cancer and gastric cancer patients. The primary outcome measures include quality of life, and secondary outcome measures encompass the severity of peripheral neuropathy, manual dexterity assessed through finger strength testing, and the effects on microcirculation blood flow in the hands and feet

NCT ID: NCT06185907 Completed - Gastric Cancer Clinical Trials

In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors

GGC-01
Start date: April 15, 2021
Phase:
Study type: Observational

The investigators plan to analyze the data of patients with gastric cancer (GC) consecutively hospitalized in Ruijin Hospital, a large tertiary center in China, comprehensively describe the characteristics of GC patients ≥65 years, and assesse their in-hospital outcomes regarding duration, fee, and death. Factors associated with the in-hospital outcomes will be further comprehensively explored.